| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Johnson & Johnson is actively advancing its product development initiatives, showcasing a commitment to long-term efficacy and safety. Recent positive data supports the effectiveness of TREMFYA® in managing Crohn's disease, which is poised to enhance market confidence. Additionally, the focus on the drug icotrokinra for plaque psoriasis highlights the company's strategy in innovating solutions for chronic conditions. These efforts, paired with strong clinical outcomes, position Johnson & Johnson favorably in the competitive healthcare landscape. |
| The price action of JOHNSON & JOHNSON (JNJ) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -0.9 is bearish. The market sentiment at 1 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for JNJ since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.2, and the negative at -0.2 on 2026-10-14. The forces of and Stock Price Trend (-0.9) will drive down the price. The forces of Price Level Sentiment (0.5), Sector Price Trend (0.6), Market Risk Appetite (0.9), Option Sentiment (1.5), Valuation Sentiment (1.9), and Sentiment towards Fundamentals (2.1) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| JNJ | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-14 | 0%(0.3%) | 253.93 | 2.85% | 19 | 35 | 38 | 2.14% | -0.39% | -0.9 | -0.1 | 1.9% | 1.1 | Short | 55% | 2.1 | 2.5 |
| 2026-10-13 | 2%(0.3%) | 248.61 | 2.81% | -4 | 30 | 30 | -5.87% | -0.73% | -1.3 | -2 | 1.9% | 0.7 | Short | 60% | 1.8 | -1.5 |
| 2026-10-12 | 0%(0%) | 264.12 | 2.31% | 48 | 43 | 91 | 1.01% | -0.31% | 0.2 | 0.6 | 1.2% | 0.6 | Long | 55% | 1.8 | -1 |
| 2026-10-11 | 0%(0%) | -0.3 | 0.6 | 0.4 | 1.6 | -1 | ||||||||||
| 2026-10-10 | 0%(0%) | -0.3 | 0.6 | 0.4 | 1.2 | -1 | ||||||||||
| 2026-10-09 | 0%(0%) | 261.49 | 2.33% | 37 | 38 | 85 | 1.96% | -0.38% | -0.3 | 0.4 | 1% | 1.1 | Long | 55% | 1.6 | -1 |
| 2026-10-08 | 0%(0%) | 256.46 | 2.36% | 15 | 27 | 39 | -0.74% | -0.53% | -0.8 | 0.2 | 1% | 0.8 | Wait | 50% | 2.1 | 6 |
| 2026-10-07 | 0%(0%) | 258.37 | 2.22% | 19 | 29 | 77 | 1.38% | -0.42% | -0.9 | 0.1 | 1.1% | 0.6 | Wait | 50% | 0.9 | -1 |
| 2026-10-06 | 0%(0%) | 254.85 | 2.17% | 0 | 27 | 58 | 0.78% | -0.57% | -1.4 | 0.1 | 0.4% | 1 | Wait | 50% | 2.3 | -1 |
| 2026-10-05 | 0%(0%) | 252.87 | 1.95% | -19 | 23 | 28 | -1.26% | -0.6% | -1.7 | -0.3 | 0.9% | 1.3 | Short | 70% | 2.2 | -1 |
| Short is the preferred trading strategy with 55% chance of being right. Weak trend sentiment and negative hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Market News | ||
| 1 (2) Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts Johnson & Johnson posted upbeat Q3 results; analysts stayed bullish, though RBC cut its target and noted mixed product and MedTech trends. (https://www.benzinga.com/) Wed. Oct 14, 2026 | ||
| 2 (5) Stock of the Day: Is this the Bottom for Johnson & Johnson? Johnson & Johnson found support near $246 after an earnings drop, with buy orders potentially signaling a bottom and rally. (https://www.benzinga.com/) Wed. Oct 14, 2026 | ||
| 3 (8) Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway Johnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook. (https://www.marketbeat.com/) Tue. Oct 13, 2026 | ||
| 4 (-8) Johnson & Johnson Stock Falls 5% After Q3 Profit Plunges Johnson & Johnson (JNJ) is down 5.12 percent, losing $13.49 to $250.24 on Monday. The decline follows the healthcare giant's third-quarter results, which showed net earnings plunging 96 percent to $210 million, or $0. (https://www.rttnews.com/) Tue. Oct 13, 2026 | ||
| 5 (-4) Johnson & Johnson Q3 Profit Declines, Lifts FY26 Outlook; Stock Drops Drug major Johnson & Johnson on Tuesday reported lower third-quarter profit mainly on a special charge related to proposed talc litigation, the acquisition of Firefly Bio, Inc. (https://www.rttnews.com/) Tue. Oct 13, 2026 | ||
| 6 (-2) Can a Spinoff Fix Johnson & Johnson’s Medtech Problem? Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter. (https://www.barrons.com/) Tue. Oct 13, 2026 | ||
| 7 (8) Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED) Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance. (https://www.benzinga.com/) Tue. Oct 13, 2026 | ||
| 8 (-4) Can a Spinoff Fix Johnson & Johnson’s Medtech Problem? Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter. (https://www.barrons.com/) Tue. Oct 13, 2026 | ||
| 9 (-4) QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss Johnson & Johnson beat third-quarter profit estimates and raised its 2026 forecast. After MedTech sales missed estimates, the stock still fell about 6%, its steepest one-day drop since April 1, 2025. XLV fell 1.1%. (https://www.benzinga.com/) Tue. Oct 13, 2026 | ||
| 10 (-4) Can a Spinoff Fix Johnson & Johnson’s Medtech Problem? Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter. (https://www.barrons.com/) Tue. Oct 13, 2026 | ||
| 11 (-6) Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today Chip stocks sold off after a 5% KOSPI plunge, with Micron and Applied Materials sinking, while J&J fell despite a guidance raise. (https://www.benzinga.com/) Tue. Oct 13, 2026 | ||
| 12 (-2) Why Johnson & Johnson Stock Dropped Today Johnson & Johnson beat earnings this morning. Then its stock price dropped. (https://www.fool.com/) Tue. Oct 13, 2026 | ||
| 13 (-3) Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit Johnson & Johnson stock is tumbling even after the healthcare giant raised its forecast again for full-year earnings and revenue. (https://finance.yahoo.com/) Tue. Oct 13, 2026 | ||
| 14 (8) Why this drug could become 'better than a $10B product': Johnson & Johnson CFO Johnson & Johnson (JNJ) reported quarterly earnings on Tuesday and raised its full-year outlook. Johnson & Johnson CFO Joseph Wolk sits down with Yahoo Finance's Julie Hyman to discuss the company's strong drug sales numbers, highlighting the excitement surrounding two medications in particular. (https://finance.yahoo.com/) Tue. Oct 13, 2026 | ||
| 15 (-5) J&J Leans Toward Orthopedic Spinoff as Medtech Sales Disappoint Johnson & Johnson reported another quarter of anemic sales in its medical technology division and said it is leaning toward spinning off, rather than selling, its orthopedics business. (https://www.bloomberg.com/) Tue. Oct 13, 2026 | ||
| 16 (7) J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027 Pharmaceutical sales jumped 7.7% in the quarter to $16.76 billion, but medical technology division sales rose just 2.5% to $8.6 billion. (https://www.cnbc.com/) Tue. Oct 13, 2026 | ||
| 17 (3) J&J beats earnings estimates; Middle East conflict weighs on medical device sales By Michael Erman Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of immune disease treatment Tremfya, but geopolitical issues (https://finance.yahoo.com/) Tue. Oct 13, 2026 | ||